Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Bluebird Bio Stock a Buy?

TheMotleyFool

0 0

Is Bluebird Bio Stock a Buy?: https://g.foolcdn.com/editorial/images/753252/patient-sitting-on-hospital-bed.jpg

Once a rising star in the biotech industry, Bluebird Bio (NASDAQ: BLUE) has had a difficult past few years. The company's shares are down by 94% since late 2018, a horrible performance by any metric. However, this biotech specialist has some redeeming qualities. Unlike most of its peers in the gene-editing niche, Bluebird has earned approval for several of its products, a testament to the company's innovative abilities.

Furthermore, Bluebird's market capitalization is just $314 million as of this writing, lower than many of its clinical-stage competitors. Is Bluebird Bio stock a buy at current levels?